WordNet
- capable of expelling or destroying parasitic worms (同)anthelminthic, helminthic, parasiticidal
- an agent that kills worms (especially those in the intestines)
- a substance that exerts some force or effect
- a businessman who buys or sells for another in exchange for a commission (同)factor, broker
- any agent or representative of a federal agency or bureau (同)federal agent
- a representative who acts on behalf of other persons or organizations
- an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
- how long something has existed; "it was replaced because of its age"
- a time of life (usually defined in years) at which some particular qualification or power arises; "she was now of school age"; "tall for his eld" (同)eld
- begin to seem older; get older; "The death of his wife caused him to age fast"
- make older; "The death of his child aged him tremendously"
PrepTutorEJDIC
- 『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
- 〈U〉(一般に)『年齢』,寿命;〈C〉(個々の)『年齢』,年 / 〈U〉成年(おとなとしての資格・権利を得る年齢;通例18または21歳) / 〈U〉『老齢』;《集合的に》老人たち / 〈U〉(人生の)『一時期』;〈C〉世代(generation) / 〈U〉〈C〉《しばしばA-》(歴史上の)『時代』 / 〈C〉《話》長い間 / 年をとる,ふける;〈物が〉古くなる / 〈年〉'を'とらせる;〈物〉'を'古びさせる
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/11/24 06:12:18」(JST)
wiki en
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. エキノコックス症の治療および予防 treatment of echinococcosis
- 2. シャーガス心臓病の治療および予後 treatment and prognosis of chagas heart disease
- 3. 回虫症 ascariasis
- 4. 嚢虫症の治療 treatment of cysticercosis
- 5. 寄生虫妄想症の治療 treatment of delusional parasitosis
English Journal
- The intravenous and oral pharmacokinetics of afoxolaner used as a monthly chewable antiparasitic for dogs.
- Letendre L1, Huang R2, Kvaternick V2, Harriman J2, Drag M2, Soll M2.Author information 1Merial Limited, 3239 Satellite Blvd, Duluth, GA 30096, USA. Electronic address: laura.letendre@merial.com.2Merial Limited, 3239 Satellite Blvd, Duluth, GA 30096, USA.AbstractThe pharmacokinetics of afoxolaner in dogs was evaluated following either intravenous or after oral administration of NEXGARD(®), a soft chewable formulation. Afoxolaner is a member of one of the newest classes of antiparasitic agents, known as antiparasitic isoxazolines. The soft chewable formulation underwent rapid dissolution, and afoxolaner was absorbed quickly following oral administration of the minimum effective dose of 2.5mg/kg, with maximum plasma concentrations (Cmax) of 1655±332ng/mL observed 2-6h (Tmax) after treatment. The terminal plasma half-life was 15.5±7.8 days, and oral bioavailability was 73.9%. Plasma concentration-versus-time curves fit a 2-compartment model and increased proportionally with dose over the oral dose range of 1.0-4.0mg/kg, and over the oral dose range from 1.0 to 40mg/kg. Following an intravenous dose of 1mg/kg, the volume of distribution (Vd) was 2.68±0.55L/kg, and the systemic clearance was 4.95±1.20mL/h/kg. Afoxolaner plasma protein binding was >99.9% in dogs. One major metabolite, formed following hydroxylation of afoxolaner, was identified in dog plasma, urine and bile. When afoxolaner is administered orally, there is a strong correlation between afoxolaner plasma concentration and efficacy with EC90 values of 23ng/mL for Ctenocephalides felis and ≥100ng/mL for Rhipicephalus sanguineus sensu lato and Dermacentor variabilis. The pharmacokinetic properties of afoxolaner are suited for a monthly administration product because the fast absorption and long terminal half-life support a rapid onset of action while ensuring month-long efficacy.
- Veterinary parasitology.Vet Parasitol.2014 Apr 2;201(3-4):190-7. doi: 10.1016/j.vetpar.2014.02.021. Epub 2014 Mar 29.
- The pharmacokinetics of afoxolaner in dogs was evaluated following either intravenous or after oral administration of NEXGARD(®), a soft chewable formulation. Afoxolaner is a member of one of the newest classes of antiparasitic agents, known as antiparasitic isoxazolines. The soft chewable formulat
- PMID 24685320
- Aminoacyl-tRNA synthetases as drug targets in eukaryotic parasites.
- Pham JS, Dawson KL, Jackson KE, Lim EE, Pasaje CF, Turner KE, Ralph SA.Author information Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Victoria 3010, Australia.AbstractAminoacyl-tRNA synthetases are central enzymes in protein translation, providing the charged tRNAs needed for appropriate construction of peptide chains. These enzymes have long been pursued as drug targets in bacteria and fungi, but the past decade has seen considerable research on aminoacyl-tRNA synthetases in eukaryotic parasites. Existing inhibitors of bacterial tRNA synthetases have been adapted for parasite use, novel inhibitors have been developed against parasite enzymes, and tRNA synthetases have been identified as the targets for compounds in use or development as antiparasitic drugs. Crystal structures have now been solved for many parasite tRNA synthetases, and opportunities for selective inhibition are becoming apparent. For different biological reasons, tRNA synthetases appear to be promising drug targets against parasites as diverse as Plasmodium (causative agent of malaria), Brugia (causative agent of lymphatic filariasis), and Trypanosoma (causative agents of Chagas disease and human African trypanosomiasis). Here we review recent developments in drug discovery and target characterisation for parasite aminoacyl-tRNA synthetases.
- International journal for parasitology. Drugs and drug resistance.Int J Parasitol Drugs Drug Resist.2013 Nov 11;4(1):1-13. eCollection 2014.
- Aminoacyl-tRNA synthetases are central enzymes in protein translation, providing the charged tRNAs needed for appropriate construction of peptide chains. These enzymes have long been pursued as drug targets in bacteria and fungi, but the past decade has seen considerable research on aminoacyl-tRNA s
- PMID 24596663
- Enhancement of Achilles tendon repair mediated by matrix metalloproteinase inhibition via systemic administration of doxycycline.
- Kessler MW1, Barr J, Greenwald R, Lane LB, Dines JS, Dines DM, Drakos MC, Grande DA, Chahine NO.Author information 1Orthopaedic Research Lab, The Feinstein Institute for Medical Research, Manhasset, New York; Georgetown University Hospital, Washington, District of Columbia.AbstractCollagenases or matrix metalloproteinases (MMPs) have been shown to play an important role in the matrix degradation cascade associated with Achilles tendon rupture and disease. The goal of this study was to examine the effects of daily administration of doxycycline (Doxy) through oral gavage on MMP activity and on the repair quality of Achilles tendons in vivo. Our findings indicate that Achilles tendon transection resulted in increasing MMP-8 activity from 2 to 6 weeks post-injury, with peak increases in activity occurring at 4 weeks post-injury. Doxy adiministration at clinically relevant serum concentrations was found to significantly inhibit MMP activity after continuous treatment for 4 weeks, but not for continuous administration for shorter durations (96 h or 2 weeks). Extended doxy administration was also associated with improved collagen fibril organization, and enhanced biomechanical properties (stiffness, ultimate tensile strength, maximum load to failure, and elastic toughness). Our findings indicate that a temporal delay exists between Achilles tendon transection and associated increases in MMP-8 activity in situ. Our findings suggest that inhibition of MMP-8 at its peak activity levels ameliorates fibrosis development and improves biomechanical properties of the Achilles tendon.
- Journal of orthopaedic research : official publication of the Orthopaedic Research Society.J Orthop Res.2014 Apr;32(4):500-6. doi: 10.1002/jor.22564. Epub 2013 Dec 18.
- Collagenases or matrix metalloproteinases (MMPs) have been shown to play an important role in the matrix degradation cascade associated with Achilles tendon rupture and disease. The goal of this study was to examine the effects of daily administration of doxycycline (Doxy) through oral gavage on MMP
- PMID 24346815
Japanese Journal
- Engineered biosynthesis of the antiparasitic agent frenolicin B and rationally designed analogs in a heterologous host
- FITZGERALD Jay T,RIDLEY Christian P,KHOSLA Chaitan
- Journal of antibiotics 64(12), 759-762, 2011-12-25
- NAID 10030640795
- 腸管糞線虫症治療薬イベルメクチン(ストロメクトール)の薬理作用 : 作用メカニズムと臨床試験成績
- 池田 孝則
- 日本薬理学雑誌 : FOLIA PHARMACOLOGICA JAPONICA 122(6), 527-538, 2003-12-01
- イベルメクチン（ストロメクトール）は放線菌Streptomyces avermitilisの発酵産物アベルメクチン類から誘導された半合成の環状ラクトン経口駆虫薬である．イベルメクチンは線虫Caenorhabditis elegans（C. elegans）の運動性を濃度依存的に阻害した．C. elegansの膜標本には，イベルメクチンに高親和性の特異的結合部位が存在し，イベルメクチン類縁体のこの結 …
- NAID 10013679999
- Antiparasitic agent atovaclone
- BAGGISH AL
- Antimicrob Agents Chemother 46, 1163-1173, 2002
- NAID 30020630528
Related Pictures
★リンクテーブル★
| リンク元 | 「駆虫剤」「anthelmintic」「抗寄生虫薬」「antiparasitic drug」「vermicide」 |
| 関連記事 | 「agent」「antiparasitic」「age」 |
「駆虫剤」
- 英
- anthelmintic, anthelmintic agent, antiparasitic agent, helminthagogue, insectifuge, vermicide, worm powder, wormer
商品
「anthelmintic」
- adj.
- 駆虫性の
- n.
「抗寄生虫薬」
「antiparasitic drug」
「vermicide」
「agent」
- n.
- 代行者、代理人。代理業者
- 政府職員、官吏
- ある後位をする人、ある作用をするもの。動員、動力因、作用因。(文法)動作主。科学的変化を起こさせるもの、薬品、～剤。病原体
- 関
- agonist、agonistic、attorney、delegate、drug、etiologic agent、fomes、fomites、mediator、pathogen、pathogenic、pharmaceutical preparation、vector、vehicle
「antiparasitic」
- adj.
- 抗寄生虫の、駆虫性の
- n.
「age」
- n.
- 年齢、歳
- v.
- 加齢する、熟成する